Clinical Trials Browser

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07218926 2026-04-03

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Phase 3 Recruiting

450 enrolled

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT07124000 2026-03-31

DP-04

Recruiting

100 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT06630234 2026-02-05

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Phase 1/2 Recruiting

120 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06655246 2026-02-05

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Phase 1 Recruiting

157 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05489237 2025-11-17

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Phase 1 Recruiting

278 enrolled

GastrointestinalSarcoma

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Phase 1 Recruiting

67 enrolled

DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma